LLY · Eli Lilly & Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B |
| Cost of Revenue | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B |
| Gross Profit | $54.13B | $36.62B | $27.04B | $21.91B | $21.01B | $19.06B |
| R&D | $13.34B | $10.99B | $6.93B | $7.19B | $7.03B | $6.09B |
| SG&A | $11.09B | $8.59B | $7.40B | $6.44B | $6.43B | $6.12B |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B | $1.32B |
| Operating Income | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B | $7.23B |
| Interest Expense | $895.00M | $780.60M | $485.90M | $331.60M | $339.80M | $359.60M |
| Income Tax | $5.09B | $2.09B | $1.31B | $561.60M | $573.80M | $1.04B |
| Net Income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B |
| EPS - Basic | $23.00 | $11.76 | $5.82 | $6.93 | $6.15 | $6.82 |
| EPS - Diluted | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B | $3.66B |
| Accounts Receivable | $17.76B | $11.01B | $9.09B | $6.90B | $6.67B | $5.88B |
| Inventory | $13.74B | $7.59B | $5.77B | $4.31B | $3.89B | $3.98B |
| Accounts Payable | $5.38B | $3.23B | $2.60B | $1.93B | $1.67B | $1.61B |
| Current Assets | $55.63B | $32.74B | $25.73B | $18.03B | $18.45B | $17.46B |
| Total Assets | $112.48B | $78.71B | $64.01B | $49.49B | $48.81B | $46.63B |
| Current Liabilities | $35.23B | $28.38B | $27.29B | $17.14B | $15.05B | $12.48B |
| Long-term Debt | $40.87B | $28.53B | $18.32B | $14.74B | $15.35B | $16.59B |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $26.54B | $14.19B | $10.77B | $10.65B | $8.98B | $5.64B |
| Retained Earnings | $24.47B | $13.54B | $10.31B | $10.04B | $8.96B | $7.83B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $16.81B | $8.82B | $4.24B | $7.08B | $7.26B | $6.50B |
| Investing Cash Flow | ($10.97B) | ($9.30B) | ($7.15B) | ($3.26B) | ($2.76B) | ($2.26B) |
| Financing Cash Flow | ($2.21B) | $1.23B | $3.50B | ($5.41B) | ($4.13B) | ($3.14B) |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 83.0% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% |
| Operating margin | 39.5% | 28.2% | 19.2% | 23.8% | 21.7% | 29.5% |
| EBITDA margin | 42.5% | 32.1% | 23.7% | 29.2% | 27.2% | 34.9% |
| Net margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | 20.5% | 24.4% | 20.3% | 25.2% | 24.8% | 24.8% |
| SG&A / Revenue | 17.0% | 19.1% | 21.7% | 22.6% | 22.7% | 24.9% |
| Effective tax rate | 19.8% | 16.5% | 20.1% | 8.3% | 9.3% | 14.3% |
| Return on assets | 18.4% | 13.5% | 8.2% | 12.6% | 11.4% | 13.3% |
| Return on equity | 77.8% | 74.6% | 48.6% | 58.6% | 62.2% | 109.8% |
| Return on invested capital | 30.6% | 24.8% | 18.0% | 24.6% | 22.9% | 27.9% |
| Liquidity | ||||||
| Current ratio | 1.58 | 1.15 | 0.94 | 1.05 | 1.23 | 1.40 |
| Quick ratio | 1.19 | 0.89 | 0.73 | 0.80 | 0.97 | 1.08 |
| Cash ratio | 0.21 | 0.12 | 0.10 | 0.12 | 0.25 | 0.29 |
| Leverage | ||||||
| Debt / Equity | 1.54 | 2.01 | 1.70 | 1.38 | 1.71 | 2.94 |
| Debt / Assets | 0.36 | 0.36 | 0.29 | 0.30 | 0.31 | 0.36 |
| Debt / EBITDA | 1.47 | 1.97 | 2.27 | 1.77 | 1.99 | 1.94 |
| Interest coverage | 28.7x | 16.2x | 13.5x | 20.5x | 18.1x | 20.1x |
| Equity multiplier | 4.24 | 5.55 | 5.94 | 4.65 | 5.44 | 8.27 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.58 | 0.57 | 0.53 | 0.58 | 0.58 | 0.53 |
| Inventory turnover | 0.80 | 1.11 | 1.23 | 1.54 | 1.88 | 1.38 |
| Days sales outstanding | 99d | 89d | 97d | 88d | 86d | 87d |
| Days inventory outstanding | 454d | 329d | 298d | 237d | 194d | 265d |
| Days payable outstanding | 178d | 140d | 134d | 106d | 83d | 107d |
| Cash conversion cycle | 376d | 278d | 261d | 219d | 197d | 245d |
| Valuation | ||||||
| P / E | 46.8x | 65.9x | 100.5x | 53.0x | 45.1x | 24.9x |
| P / B | 36.4x | 49.2x | 48.9x | 31.1x | 28.0x | 27.3x |
| P / S | 14.8x | 15.5x | 15.4x | 11.6x | 8.9x | 6.3x |
| EV / EBITDA | 36.1x | 50.1x | 67.1x | 41.3x | 34.2x | 19.5x |
| Growth | ||||||
| Revenue growth (YoY) | 44.7% | 32.0% | 19.6% | 0.8% | 15.4% | 9.9% |
| Revenue CAGR (3y) | 31.7% | 16.7% | 11.6% | 8.5% | 4.9% | 2.4% |
| Revenue CAGR (5y) | 21.6% | 15.1% | 6.8% | 4.5% | 5.9% | 4.2% |
| Gross profit growth (YoY) | 47.8% | 35.4% | 23.4% | 4.3% | 10.2% | 8.3% |
| Operating income growth (YoY) | 102.9% | 93.5% | -3.7% | 10.6% | -14.9% | 37.3% |
| Net income growth (YoY) | 94.9% | 102.1% | -16.1% | 11.9% | -9.9% | -25.5% |
| EPS growth (YoY) | 96.0% | 101.9% | -15.9% | 12.7% | -9.9% | -23.6% |
| EPS CAGR (3y) | 49.3% | 24.1% | -5.1% | -8.1% | 25.0% | - |
| EPS CAGR (5y) | 27.6% | 5.7% | 13.1% | - | 18.9% | 24.6% |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 87.0% | 31.8% | 1.1% | 18.6% | 59.2% | 116.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$65.18B totalReportable Segment$65.18B · 100.0%
Product / service
$150.84B totalProduct$60.96B · 40.4%
Cardiometabolic Health$33.86B · 22.5%
Mounjaro$13.65B · 9.0%
Zepbound$13.48B · 8.9%
Oncology$5.35B · 3.5%
Collaborationand Other Revenue$4.22B · 2.8%
Verzenio$3.46B · 2.3%
Immunology$2.96B · 2.0%
Trulicity$2.91B · 1.9%
Taltz$2.33B · 1.5%
Other Cardiometabolic Health$2.23B · 1.5%
Other Oncology$1.89B · 1.3%
Jardiance$1.58B · 1.0%
Neuroscience$997.00M · 0.7%
Other Immunology$631.00M · 0.4%
Other Product Total$304.00M · 0.2%
Geographic
$86.88B totalUS$43.48B · 50.0%
Non Us$21.70B · 25.0%
Europe$11.56B · 13.3%
Rest Of World$6.06B · 7.0%
JP$2.13B · 2.5%
CN$1.95B · 2.2%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
7/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ELI LILLY & Co against the 5 most active filers in the same SIC group.
Dividends
$6.46/share trailing 12 months · +15.4% YoY
| Ex-date | Per share |
|---|---|
| May 15, 2026 | $1.7300 |
| Feb 13, 2026 | $1.7300 |
| Nov 14, 2025 | $1.5000 |
| Aug 15, 2025 | $1.5000 |
| May 16, 2025 | $1.5000 |
| Feb 14, 2025 | $1.5000 |
| Nov 15, 2024 | $1.3000 |
| Aug 15, 2024 | $1.3000 |
| May 15, 2024 | $1.3000 |
| Feb 14, 2024 | $1.3000 |
| Nov 14, 2023 | $1.1300 |
| Aug 14, 2023 | $1.1300 |
| May 12, 2023 | $1.1300 |
| Feb 14, 2023 | $1.1300 |
| Nov 14, 2022 | $0.9800 |
| Aug 12, 2022 | $0.9800 |
| May 13, 2022 | $0.9800 |
| Feb 14, 2022 | $0.9800 |
| Nov 12, 2021 | $0.8500 |
| Aug 12, 2021 | $0.8500 |
| May 13, 2021 | $0.8500 |
| Feb 11, 2021 | $0.8500 |
| Nov 12, 2020 | $0.7400 |
| Aug 13, 2020 | $0.7400 |